Tagged with M

Pharma Legal Handbook All legal aspects of marketing, manufacturing, packaging, labeling and advertising of drugs in Estonia. Prepared in association with TGS Baltic, a leading law firm in Estonia, this is an extract from The Pharma Legal Handbook: Baltics, available to purchase here for GBP 99.   1. What is the authorization process for the…

Pharma Legal Handbook All legal aspects surrounding preclinical and clinical trials in Estonia. Prepared in association with TGS Baltic, a leading law firm in Estonia, this is an extract from The Pharma Legal Handbook: Baltics, available to purchase here for GBP 99.   1. Are clinical trials required to be conducted locally as a condition…

Pharma Legal Handbook All legal aspects surrounding regulatory, pricing and reimbursement in Estonia. Prepared in association with TGS Baltic, a leading law firm in Estonia, this is an extract from The Pharma Legal Handbook: Baltics, available to purchase here for GBP 99.   1. What are the regulatory authorities with jurisdiction over drugs,…

China The latest news from Chinese pharma, including a new report showing that despite the increasing number of Priority Review and Breakthrough Therapy designations awarded within China, only two Accelerated Approval designations have been awarded since 2015. Elsewhere, Pfizer is utilising drone technology to promote health education in remote areas and…

Global With advances in technology, an increasing number of stable peptide-based therapeutics are being brought to market today across a wide range of therapeutic areas. Through expert insight, we explain why the peptide field is generating so much excitement, outline some of the most significant recent breakthroughs and big-ticket investments, and…

Turkey Getinge’s president for Central and Eastern Europe, Ahmet Eke, comments on the strategic importance of the region for the Swedish company, the evolution of healthcare infrastructure in Turkey, and how Getinge competes in emerging markets against European and American medtech players.   Like many emerging markets, monetary resources are limited…

Turkey While supporters of Turkey’s localization policy for pharmaceuticals implemented in 2016 applaud the changes it has brought, its opponents are awaiting a much-anticipated report by the World Trade Organization that could put an end to the policy and have global repercussions.   Five years after the launch of Turkey’s localization…

MENA The Middle East and Africa (MEA) region is vast and is predominantly composed of emerging countries with varying levels of income and healthcare infrastructure. Here, three regional managers for pharma multinationals explain what MEA means to their global groups and their key areas of focus today.   Biogen: Awareness is…

Global After a challenging 2020, and with more hurdles in sight, Bayer has been on an investment spree with a USD 2 billion acquisition of a San Diego-based biotech and manufacturing sites in Latin America and Norway.   Bayer had a challenging year in 2020. While the German giant argued in…

Asia-Pacific Asia has experienced a biotech boom in the past five years. In 2020, almost 50 percent of the region’s clinical trials were led by biotechs and by 2025, biotech-led clinical trials will far exceed those led by Big Pharma, according to IQVIA. However, the region’s biotechs face a myriad of…

Denmark Newly appointed Director of Invest in Denmark Anne Hougaard Jensen outlines her initial priority list, how the agency is dialling in on the areas in which Denmark has a particular competitive advantage (life sciences, food, green technologies, and digital technologies), and her aspirations for keeping Denmark ahead of the curve…

Turkey General manager of Core Diagnostic at Abbott Turkey Yelda Ulu Colin highlights the company’s prominent role during the pandemic, including the launch of the first antibody serology testing solution just one month after the World Health Organization made an official pandemic declaration. In addition, she categorizes the government’s response to…